Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00450112 · ClinicalTrials.gov registry record · Phase 3
Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee
A Phase 3 study, sponsored by Seikagaku Corporation.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT00450112 is a Phase 3 study that has completed, run by Seikagaku Corporation. The registered enrollment target is 202 participants.
The verdict
NCT00450112, a Phase 3 study, has completed, sponsored by Seikagaku Corporation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a single or repeat intra-articular injection of Gel-200 is safe and effective in subjects with symptomatic osteoarthritis of the knee and to determine if original SI-6606/01 Gel-200 therapy is durable beyond the original study.
Interventions
- DEVICE Gel-200
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2007-03 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00450112
The ClinicalTrials.gov registry entry for NCT00450112 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seikagaku Corporation, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gel-200 is the first listed.
NCT00450112 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00450112 about?
NCT00450112 is a clinical study titled "Gel-200 Extension and Open-Label Study in Osteoarthritis of the Knee". The purpose of this study is to determine if a single or repeat intra-articular injection of Gel-200 is safe and effective in subjects with symptomatic osteoarthritis of the knee and to determine if original SI-6606/01 Gel-200 therapy is durable beyond the original study.
What is the current status of trial NCT00450112?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2007-03. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00450112?
The interventions under investigation include: Gel-200 (DEVICE).
Who is sponsoring clinical trial NCT00450112?
This trial is sponsored by Seikagaku Corporation, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.